Latest news with #PCP
Business Upturn
3 days ago
- Business
- Business Upturn
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company'), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the 'Offering') of 2,666,667 ordinary shares (the 'Ordinary Shares') at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol 'MENS'. The Offering closed on June 18, 2025. The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover over-allotments, if any. The Company intends to use the net proceeds from the Offering for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%). The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as sole underwriter for the Offering (the 'Underwriter'). Sichenzia Ross Ference Carmel LLP acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. securities counsel to the Underwriter, in connection with the Offering. A registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on June 16, 2025. The Offering was made only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained from Joseph Stone Capital, LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at [email protected] or by telephone at +1 (888) 302-5548. In addition, a copy of the final prospectus relating to the Offering, dated June 16, 2025, can also be obtained via the SEC's website at Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the intended use of the proceeds from the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: UnderwriterJoseph Stone Capital, LLC (888) 302-5548 [email protected]
Yahoo
06-06-2025
- Yahoo
DC police searching for suspect wanted for hit-and-run that injured a boy
WASHINGTON () — D.C. police are looking for the suspect who may be involved in a hit-and-run. The Metropolitan Police Department (MPD) said on June 2, at around 4:30 p.m., the suspect was riding a scooter in the 3000 block of Warder Street. DC man found guilty of distributing PCP The victim, a juvenile boy, was crossing the street on a push scooter when the suspect hit the boy and they both fell. The suspect got up and got back on the scooter before leaving. The boy was taken to the hospital with non-life-threatening injuries. The suspect was riding a motorized Honda cycle with Maryland tag 5830Y. Anyone with information is asked to call (202) 727-9099 or text 50411. A reward of up to $1,000 is being offered to anyone with information that leads to an arrest and indictment of those involved. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
06-06-2025
- Yahoo
DC man found guilty of distributing PCP
WASHINGTON (DC News Now) — A D.C. man was found guilty of conspiracy to distribute and possess with intent to distribute phencyclidine (PCP). The U.S. Attorney's Office (USAO) for D.C. said in a news release that a jury found 44-year-old Norman Morris — also known as 'Fibble' — guilty on Tuesday. Court documents say that the Drug Enforcement Administration (DEA) and the FBI started conducting an investigation in September 2023 into a group that included Morris and some other co-defendants. DC man sentenced for robbing woman, stealing car Prosecutors say that Morris was conducting drug transactions outside of his home in the 200 block of 58th St. NE. Law enforcement monitored these transactions for several months, during which time officers saw Morris' co-defendants meet with him to exchange possible narcotics and cash. The USAO said that one of his co-defendants, 45-year-old Jamar Bennett, sold over two kilograms of PCP to undercover officers over nine different transactions. Another co-defendant, 44-year-old Lamont M. Langston, provided the PCP, and a third co-defendant, 43-year-old Kelvin Sanker, prepared and stored the PCP at his home. Bennett pleaded guilty to charges on April 11, 2024. Sanker pleaded guilty on Oct. 22, 2024. Langston pleaded guilty on Dec. 19, 2024. The date for Morris' sentencing would be set later. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Daily Mirror
02-06-2025
- Entertainment
- Daily Mirror
Kylie Jenner's hairstylist's cause of death confirmed four months after tragedy
Celebrity hairstylist Jesus Guerrero worked with the likes of Kylie Jenner and Jennifer Lopez but died in February aged just 34. His cause of death has now been confirmed The cause of death of a celebrity hairstylist has been confirmed four months after his passing. Jesus Guerrero died in Los Angeles in February, with his passing shocking his celebrity clientele. Among those on his roster were Kylie Jenner, Katy Perry Jennifer Lopez. Guerrero died in hospital shortly after working with J-Lo in Dubai. He was aged just 34. According to a report, Guerrero died from a severe form of pneumonia. According to the Los Angeles County Department of Medical Examiner, the stylist's cause of death was listed as Pneumocystis jirovecii pneumonia (PCP), which is a fungal infection that usually affects people with weakened immune systems. Also listed was Cryptococcosis neoformans, which is a serious fungal infection that can spread to a number of organs and tissues in the body. The secondary cause listed was Acquired Immunodeficiency Syndrome (AIDS). The manner of death was listed as natural. His death was confirmed at the time by his younger sister Gris. She shared an emotional post - and revealed the family had set up a GoFundMe page in his honour. She wrote in her touching message: "My name is Gris, Jesus's younger sister. It is with a heavy heart that we let the world know that Jesus Guerrero has gone to heaven. He is a son, a brother, an uncle, an artist, a friend, and so much more." She added: "Born and raised in Houston, TX to immigrant parents, Jesus learned how to work hard and dreamt of taking his skills to the top. Unfortunately, his passing came very suddenly and unexpectedly. Currently, his family is taking care of his personal belongings and accommodations to bring him home to Houston. "We hope that you find it in your heart to help in any way and/or share this GoFundMe." After sharing a touching tribute shortly after his death, reality TV star and business mogul Kylie said that the 'ache of missing' her late hair stylist 'hit all over again' as she continued to come to terms with his death two months on. She had generously stepped forward to help his family with the funeral expenses which was held held in Texas in March. Expressing her ongoing heartache on Instagram in April, the Keeping Up with the Kardashians alum said: "Found this video from [October 2024]. I thought I could get through today without crying, but the ache of missing you hit all over again. "Grief isn't getting easier, it's getting lonelier. I miss you so much. Why aren't you here? Every first without you hurts [so much]." Her initial heartfelt tribute had read: "Thank you, Jesus, for always being there for me, for lifting me up, for being my friend. The pain of losing you is just unbearable and I don't know how to move forward without you but I know great grief is born only of great love. and I loved you so much. "You were the best person, with a talent that was unmatched. a true artist. You inspired so many, and you always will. Your words, your laughter, your kindness, your beautiful spirit will live in my heart forever. "I'll cherish all our moments together. every laugh and hug. I wish I could hug you again. I laid in your bed the way you used to lay in mine, talking for hours. I would give anything for one more deep talk. I'm going to miss you so much. more than any words can say. 222 my angel."
Yahoo
02-06-2025
- Entertainment
- Yahoo
Kylie Jenner's Hairstylist Cause of Death Revealed 3 Months After His Passing
Kylie Jenner's late hairstylist, Jesus Guerrero's cause of death, has been revealed three months after his tragic passing. Per a report from the Los Angeles County Medical Examiner, published this week, the celebrity hairdresser died of natural causes. Guerrero contracted two infections — pneumocystis jirovecii pneumonia (PCP) and disseminated cryptococcus neoformans — which are both caused by fungus, according to the Centers for Disease Control. The medical examiner listed the secondary cause of death as Acquired Immunodeficiency Syndrome. Guerrero died in February at age 34. His sister, Gris Guerrero, spoke to Us Weekly in March and said that her brother was diagnosed with gastritis months back and was very private about his health. 'People who saw him said, 'You need to get rest and help,' and he seemed to believe he could push through it and get better and unfortunately that wasn't the case,'' she told the outlet. Besides being part of The Kardashians star's glam team, Jesus was also a close friend to her. Following Jesus' passing, Gris created a GoFundMe page — and was moved when Jenner, 27, reached out to help financially. 'Our family deeply appreciates Kylie for later offering to cover funeral expenses and offering up all her help and support,' Gris wrote. The Khy founder, along with Jennifer Lopez, another one of Jesus' A-list clients, attended the funeral, which took place in Houston in March. Jenner posted about how much she missed Jesus on her Instagram Story last month. 'Think about u every day,' she wrote on a photo of Jesus cooking in the kitchen with her and her daughter Stormi, 7, whom she shares with her ex Travis Scott. She also made a heartfelt tribute to Jesus on the app in February after news of his death broke. 'Jesus was more than my friend – he was a light in my life, a source of laughter, comfort, love, and unwavering support,' she wrote in part. 'I don't know how I would have made it through the last almost decade without him by my side. He had a way of making even the heaviest days feel lighter.'
